Tag Archive | "cisplatin"

Type 2 diabetes drug could be beneficial for head and neck cancer patients

Sunday, June 5, 2016

0 Comments

Source: www.eurekalert.org Author: press release Researchers at the University of Cincinnati (UC) College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could […]

Continue reading...

Cetuximab plus RT linked with high toxicity in head and neck cancer

Sunday, December 13, 2015

0 Comments

Source: www.cancernetwork.com Author: Anna Azvolinsky, PhD The combination of radiation therapy plus the EGFR inhibitor cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) compared with radiation therapy plus the chemotherapy cisplatin, according to results of a phase II trial based in Italy. […]

Continue reading...

Follow-up by advance practice nurses improves care for patients with head, neck cancer

Tuesday, November 3, 2015

0 Comments

Source: www.healio.com Author: Anthony SanFilippo The launch of an advance practice nurse outpatient follow-up clinic improved symptom management for high-risk patients with head and neck cancer following radiation therapy, according to findings from a study conducted at Cleveland Clinic. This initiative led to fewer ED visits and hospital admissions, results showed. “These results are significant […]

Continue reading...

Less Is More for HPV Oropharyngeal Cancer Reduced-intensity regimen clears disease in 86% of cases

Wednesday, October 21, 2015

0 Comments

Source: www.medpagetoday.com Author: Charles Bankhead   SAN ANTONIO — Less intense treatment of low-risk human papillomavirus (HPV)-related oropharyngeal cancer achieved a high rate of pathologic complete response (pCR) and favorable patient-reported outcomes, a preliminary trial showed. Overall, 37 of 43 (86%) patients achieved pCR with deintensified chemoradiation, including all but one evaluable primary tumor. The […]

Continue reading...

Critical Outcome Technologies and MD Anderson Cancer Center to evaluate COTI-2 in treating head and neck cancers

Thursday, October 23, 2014

0 Comments

Source: www.marketwatch.com Author: press release Critical Outcome Technologies Inc. (“COTI”), the bioinformatics and accelerated drug discovery company, announced today that it recently executed a material transfer agreement (“MTA”) with Dr. Jeffery Myers, MD, PhD, FACS of The University of Texas MD Anderson Cancer Center for the continued evaluation of COTI-2 in the potential treatment of […]

Continue reading...

Low-dose IMRT may be safe for patients with HPV-positive head and neck cancer

Tuesday, June 3, 2014

0 Comments

Source: www.oncologypractice.com Author: Laura Nikolaides Lower-dose radiation therapy may be safe for some patients with human papillomavirus (HPV)-positive oropharyngeal cancer, decreasing the risk of often long-term side effects, such as trouble swallowing, dry mouth, loss of taste, neck stiffness, and thyroid problems, investigators reported at the annual meeting of the American Society of Clinical Oncology. […]

Continue reading...

Aspirin may stop deafness caused by chemotherapy

Sunday, May 11, 2014

0 Comments

Source:  www.bbc.com Author: staff Aspirin could save the hearing of cancer patients receiving chemotherapy, scientists in Cardiff hope. A trial will be launched at the city’s Velindre Hospital to see if high doses of the drug can prevent permanent loss. Conditions ranging from tinnitus to deafness are a common side effect for patients given the […]

Continue reading...

Experimental EGFR inhibitor added nothing but rash

Wednesday, March 19, 2014

0 Comments

Source: www.oncologypractice.com Author: Neil Osterweil, Oncology Report Digital Network The addition of the experimental targeted agent zalutumumab to primary curative chemoradiation for head and neck cancers did not improve locoregional control, disease-specific survival, or overall survival at 3 years of follow-up. The only thing that zalutumumab added to therapy was a skin rash in the […]

Continue reading...

Chemoradiation offered better survival than accelerated radiation in head and neck squamous cell carcinomas

Wednesday, March 19, 2014

0 Comments

Source: www.oncologypractice.com Author: Neil Osterweil, Oncology Report Digital Network Concurrent chemoradiation offered better overall survival and disease-free survival than accelerated radiotherapy in patients with moderately advanced squamous cell carcinomas of the head and neck, investigators reported at the Multidisciplinary Head and Neck Symposium. Actuarial rates of 2-year overall survival and disease-free survival in patients treated […]

Continue reading...

PTEN loss, PIK3CA mutation predicted resistance to cetuximab in HNSCC

Monday, June 3, 2013

0 Comments

June 2, 2013 Source: Helio.com   CHICAGO — PTEN loss or PIK3CA mutation predicted resistance to treatment with cisplatin plus cetuximab in a cohort of patients with head and neck squamous cell carcinoma, according to phase 3 study results presented at the ASCO Annual Meeting. “Cetuximab is the only targeted therapy in use in head […]

Continue reading...